Tumor heterogeneity: does it matter?. Issue 10 (3rd October 2019)

• Record Type: Journal Article
• Authors: Turnquist, Casmir; Watson, Robert A; Protheroe, Andrew; Verrill, Clare; Sivakumar, Shivan
• Is Part Of: Expert review of anticancer therapy. Volume 19:Issue 10(2019)
• Page Start: 857
• Page End: 867
• Publication Date: 2019-10-03
• Subjects: Cancer stem cell -- drug resistance -- liquid biopsy -- tumor evolution -- tumor heterogeneity; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2019.1667236
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction : It has long been recognized that tumors are composed of a mosaic of cells and numerous methods have been developed to detect tumor heterogeneity, including in situ hybridization, multi-regional sampling, cytological assays, and whole genome and single cell sequencing. Using these methods, heterogeneity has been observed at the genetic, epigenetic, and phenotypic level in numerous cancers. With the advent of deep sequencing technology, we now appreciate a greater complexity of distinct genotypes and phenotypes that drive the biological behavior of cancer. Despite decades of progress in detecting tumor heterogeneity, the question remains: to what extent does it matter? Areas covered : This review explores the evidence for and against the importance of tumor heterogeneity in three main areas: prognostication, development of targeted therapeutics and tumor resistance; summarizing current understanding before evaluating ongoing experimental and clinical developments. Expert opinion : Theoretical understanding and in vitro detection of intratumour heterogeneity promises much but is yet to translate into meaningful clinical benefit. However, the recent emergence of a host of technological innovations and upcoming clinical trials may soon change the landscape of this field.